Paranos and colleagues reported discovery and characterization of a jumbo bacteriophage active against metallo‑β‑lactamase (MBL)–producing Pseudomonas aeruginosa strains. The study describes host range, genomic features and in vitro lytic activity against clinical multidrug‑resistant isolates, and positions the phage as a candidate for compassionate‑use or adjunctive therapies in refractory infections. Authors discuss formulation, delivery and regulatory considerations for phage therapy and underscore the need for controlled clinical trials to evaluate safety, dosing and synergy with antibiotics. The work renews industry attention on bacteriophage drug development for priority pathogens.